Evidence map›Paper›PMID 29283509›Full record

ArticleCardiovascular therapeutics2018

Exenatide exhibits anti-inflammatory properties and modulates endothelial response to tumor necrosis factor α-mediated activation.

Wojciech Garczorz, Enrique Gallego-Colon, Agnieszka Kosowska, Agnieszka Kłych-Ratuszny, Michał Woźniak, Wiesław Marcol, K J Niesner, Tomasz Francuz

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04122716. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04122716 phase4unknown status

Synergy Effect of the Appetite Hormone GLP-1 (LiragluTide) and Exercise on Maintenance of Weight Loss and Health After a Low Calorie Diet - the S-LiTE Randomized Trial

Ran2016Enrolled215Registered outcomes28Posted comparisons0ConditionsObesityArmsExercise, liraglutide
PMID 23186644PMID 26132939PMID 26284720PMID 28049736PMID 30052921PMID 27295427PMID 27633186PMID 25287751PMID 23812094PMID 18663167PMID 9449682PMID 7632212other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Gut Molecules in Cardiometabolic Diseases: The Mechanisms behind the Story.International journal of molecular sciences · 2023
    Review
  10. Article
  11. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2023
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Wojciech GarczorzDepartment of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.ORCID http://orcid.org/0000-0002-5343-1205
Enrique Gallego-ColonDepartment of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.ORCID http://orcid.org/0000-0002-3513-6464
Agnieszka KosowskaDepartment of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Agnieszka Kłych-RatusznyDepartment of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Michał WoźniakDepartment of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Wiesław MarcolDepartment of Physiology, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
K J NiesnerCollege of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.ORCID http://orcid.org/0000-0001-6966-5340
Tomasz FrancuzDepartment of Biochemistry, School of Medicine in Katowice, Medical University of Silesia, Katowice, Poland.
Medical University of Silesia · PLUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCardiovascular disease is the main cause of mortality and morbidity in the industrialized world. Incretin-mimetic compounds such as exenatide are currently used in the treatment of type 2 diabetes.

aimsWe investigated the effects of incretin drugs on apoptosis, adhesion molecule expression, and concentration of extracellular matrix (ECM) metalloproteinases under inflammatory conditions within the context of atherosclerotic plaque formation of both human coronary artery endothelial cells (hCAECs) and human aortic endothelial cells (hAoECs). TNF-α-stimulated hCAEC and hAoEC were treated with exenatide (1 and 10 nmol/L) and GLP-1 (10 and 100 nmol/L) then evaluated for caspase 3/7 activity and assayed for protein levels of adhesion molecules sICAM-1, sVCAM-1, and P-selectin. Concentrations of matrix metalloproteinases (MMPs) MMP-1, MMP-2, MMP-9, and their inhibitors-tissue inhibitor of metalloproteinases (TIMPs), TIMP-1, TIMP-2 were also measured to evaluate the effects on extracellular matrix turnover within an inflammatory environment. Intracellular signaling pathways were evaluated via transfection of endothelial cells with a GFP vector under the NF-κB promoter.

resultsOur experimental data suggest that GLP-1 receptor (GLP-1R) agonists downregulate activation of NF-κB and adhesion molecules ICAM and VCAM, but not P-selectin, in both endothelial cell lines. Exendin-4 and GLP-1 modulate the expression of MMPs and TIMPs, with statistically significant effects observed at high concentrations of both incretins. Expressive modulation may be mediated by NF-κB as observed by activation of the vector when stimulated under inflammatory conditions.

conclusionThese findings indicate that GLP-1 analogs have anti-inflammatory properties in endothelial cells that may play an important role in preventing atherosclerosis.

Indexed as

Anti-Inflammatory AgentsApoptosisCaspasesCell Adhesion MoleculesCells, CulturedDose-Response Relationship, DrugEndothelial CellsExenatideExtracellular MatrixGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsHumansMatrix MetalloproteinasesNF-kappa BPeptidesSignal TransductionAnti-Inflammatory AgentsCaspasesCell Adhesion MoleculesExenatideGLP1R protein, humanGlucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsMatrix MetalloproteinasesNF-kappa BPeptidesTissue Inhibitor of MetalloproteinasesTumor Necrosis Factor-alphaVenomsadhesion moleculesatherosclerosisexenatideExendin-4human aortic endothelial cellshuman coronary artery endothelial cellsincretinsmatrix metalloproteinasesNF-κBtumor necrosis factor-α

Identifiers

PMID29283509
OpenAlexW2778344573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.